Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II interventional trial to evaluate the efficacy of ponatinib plus
reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute
lymphoblastic leukemia. This combination has the potential to improve the depth of molecular
responses after the induction phase of treatment. Patients who achieve a complete molecular
response (CMR) at week 11 will not be directed to alloSCT and will receive consolidation
chemotherapy combined with ponatinib, followed by 24 months of ponatinib maintenance. The aim
is to spare individuals with a low probability of relapse from overtreatment with more
intensive and toxic transplant procedure.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Hematology and Blood Transfusion, Czech Republic
Collaborator:
CZECRIN - Czech Clinical Research Infrastructure Network